GCG and chronic kidney disease: Many guidelines state that the use of SGLT2I, GLP1 agonist, or finerenone, or their combination therapies in addition to ARBs, especially in chronic kidney disease patients with heart failure or diabetes, are beneficial and should be added to treatment algorithms [4,21,22].